RECURRENT ENDOMETRIAL CANCER
Clinical trials for RECURRENT ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug ART0380 trial halted early
Disease control TerminatedThis study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The drug was taken by mouth and aimed to shrink tumors by blocking a protein involved in cancer cell growth. The trial was terminated early, …
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising cancer combo study halted early – only 4 black women enrolled
Disease control TerminatedThis study aimed to see if a combination of two drugs, lenvatinib and pembrolizumab, could shrink tumors in Black women with a certain type of recurrent endometrial cancer. Only 4 participants were enrolled before the study was stopped early. The goal was to measure how many pati…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC